TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Eyepoint, Inc.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint announced progress on its lead product DURAVYU (vorolanib intravitreal insert) with Phase 3 wet AMD trials on track for data readout beginning mid-2026 and Phase 3 DME program first patient dosing expected in Q1 2026. The company completed enrollment of over 900 patients across wet AMD trials in 7 months and has approximately $300 million in cash runway into Q4 2027.

Insights
OGN   neutral

Mentioned as a leading market company without specific growth or innovation details


EYPT   positive

Company achieved rapid enrollment milestones (900+ patients in 7 months), secured $172.5 million in funding, has strong cash runway through Q4 2027, and is positioned as potentially first-to-market among investigational sustained delivery programs for wet AMD with data expected mid-2026. Independent DSMC recommended continuation without protocol modifications, indicating positive safety profile.